Hepta Bio
Biotechnology company developing non-invasive diagnostic tests for liver disease, aiming to replace liver biopsies with blood-based testing for conditions like NASH and fibrosis.
Notes
Hepta Bio is developing non-invasive diagnostics for liver disease, addressing the significant clinical need for better methods to assess liver health without requiring invasive biopsies. The company focuses on conditions like non-alcoholic steatohepatitis (NASH) and liver fibrosis, which affect millions of patients globally.
Current gold-standard diagnosis for liver fibrosis and NASH requires liver biopsy, an invasive procedure with risks and limitations including sampling variability. Hepta Bio's technology aims to provide more accurate, accessible, and patient-friendly diagnostic options.
The company operates in the growing space of liver disease diagnostics, which has become increasingly important as obesity and metabolic syndrome drive rising rates of fatty liver disease worldwide.
Team
- Leadership team with experience in diagnostics and hepatology
Additional Research Findings
- Founded circa 2020, based in Boston area
- Non-invasive liver disease diagnostics
- Focus on NASH and fibrosis assessment
- Blood-based testing approach
- Addresses need to replace liver biopsies
- Growing market due to NASH epidemic
- Early-stage development company
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Illumina Ventures | San Francisco, California, USA | biotech-focused | seedseries-a+1 | 32 |